Ibrexafungerp (citrate), CAS 1965291-08-0

Product Description: Ibrexafungerp citrate (MK 3118 citrate) is an orally active β-1,3-glucan synthesis inhibitor, with potential antifungal activity. Ibrexafungerp citrate is an investigational agent for the treatment of Candida and Aspergillus infections[1].

Applications: COVID-19-immunoregulation

Formula: C50H75N5O11

References: [1]James M Apgar, et al. Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor. Bioorg Med Chem Lett. 2021 Jan 15;32:127661./[2]Mahmoud Ghannoum, et al. Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections. Antibiotics (Basel). 2020 Aug 25;9(9):539./[3]Stephen A Wring, et al. Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis. Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02068-16.

CAS Number: 1965291-08-0

Molecular Weight: 922.16

Compound Purity: 99.10

Research Area: Infection

Solubility: DMSO : 100 mg/mL (ultrasonic)

Target: Fungal

• Artikelnummer: MEXHY-107126A-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-107126A-5
• Green Labware: Nein
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK